A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis Clinical Trial

Official title:

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06143878
• Other study ID #: 77242113PSO3002
• Secondary ID: 77242113PSO3002
• Status: Recruiting
• Phase: Phase 3
• Start date: January 17, 2024
• Est. completion date: June 1, 2027

Study information

• Verified date: June 2024
• Source: Janssen Research & Development, LLC
• Contact: Study Contact
• Phone: 844-434-4210
• Email: Participate-In-This-Study[@]its.jnj.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 750
• Est. completion date: June 1, 2027
• Est. primary completion date: March 13, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention

• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline

• Total psoriasis area and severity index (PASI) >=12 at screening and baseline

• Total investigator global assessment (IGA) >=3 at screening and baseline

• Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

• Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)

• Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)

• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances

• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention

• Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• JNJ-77242113
JNJ-77242113 will be administered orally.
• JNJ-77242113 Matching Placebo
JNJ-77242113 matching placebo will be administered orally.
• Deucravacitinib
Deucravacitinib will be administered orally.
• Deucravacitinib Matching Placebo
Deucravacitinib matching placebo will be administered orally.

Locations

Country	Name	City	State
Argentina	ARCIS Salud SRL Aprillus asistencia e investigacion	Buenos Aires
Argentina	Instituto Medico De Alta Complejidad (IMAC)	Buenos Aires
Argentina	Halitus Instituto Medico S.A. - Dermatologia y Estetica	Caba
Argentina	Hospital Italiano de Buenos Aires	Caba
Argentina	Instituto de Neumonologia y Dermatologia	Caba
Argentina	Hospital Italiano de La Plata	La Plata
Argentina	Instituto Caici Srl.	Rosario
Argentina	Centro de Investigaciones Medicas Tucuman	San Miguel De Tucuman
Australia	North Eastern Health Specialists	Campbelltown
Australia	Paratus Clinical Research Woden	Canberra
Australia	Sinclair Dermatology	East Melbourne
Australia	Skin Health Institute Inc.	Melbourne
Australia	Veracity Clinical Research	Woolloongabba
Brazil	Fundacao do ABC - Centro Universitario FMABC	Santo Andre
Canada	CCA Medical Research Corporation	Ajax	Ontario
Canada	SimcoDerm Medical and Surgical Dermatology Centre	Barrie	Ontario
Canada	Dermatrials Research	Hamilton	Ontario
Canada	York Dermatology Clinic and Research Centre	Richmond Hill	Ontario
Canada	Karma Clinical Trials Inc.	St. John's	Newfoundland and Labrador
Canada	Enverus Medical	Surrey	British Columbia
Canada	Alliance Clinical Trials	Waterloo	Ontario
Canada	XLR8 Medical Research	Windsor	Ontario
Germany	ISA - Interdisciplinary Study Association GmbH	Berlin
Germany	Hautarztpraxis	Bramsche
Germany	Klinische Forschung Dresden GmbH	Dresden
Germany	Praxis für Dermatologie und Venerologie	Dresden
Germany	Universitaetsklinikum Duesseldorf	Duesseldorf
Germany	MensingDerma research GmbH	Hamburg
Germany	Universitaetsklinikum Hamburg Eppendorf	Hamburg
Germany	Universitaetsklinikum Schleswig-Holstein Campus Kiel	Kiel
Germany	Studienzentrum Dr Schwarz Germany	Langenau
Germany	Universitatsklinikum Leipzig AOR	Leipzig
Germany	Universitatsklinikum Schleswig Holstein Campus Lubeck	Lubeck
Germany	Universitaetsklinikum Mannheim	Mannheim
Germany	Klinik und Poliklinik fur Dermatologie und Allergologie am Biederstein	Munchen
Germany	Hautarztpraxis	Potsdam
Germany	Universitaetsmedizin Rostock	Rostock
Hungary	Pecsi Tudomanyegyetem	Borgyogyaszati Klinika
Hungary	Obudai Egeszsegugyi Centrum Kft	Budapest
Hungary	Debreceni Egyetem Klinikai Kozpont	Debrecen
Hungary	Derma-B Kft	Debrecen
Hungary	Somogy Varmegyei Kaposi Mor Oktato Korhaz	Kaposvar
Hungary	SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika	Szeged
Hungary	Allergo-Derm Bakos Kft.	Szolnok
Hungary	Medmare Egeszsegugyi Es Szolgaltato Bt.	Veszprem
Japan	Fukuoka University Hospital	Fukuoka
Japan	Hino Dermatology Clinic	Fukutsu
Japan	Gifu University Hospital	Gifu
Japan	Gunma University Hospital	Gunma
Japan	Asahikawa Medical University Hospital	Hokkaido
Japan	JR Sapporo Hospital	Hokkaido
Japan	Tokai University Hospital	Isehara
Japan	Teikyo University Hospital	Itabashi Ku
Japan	St Marianna University Hospital	Kawasaki City
Japan	Hospital of the University of Occupational and Environmental Health	Kitakyushu-shi
Japan	Nagoya City University Hospital	Nagoya
Japan	University of the Ryukyus Hospital	Nishihara
Japan	Takagi Dermatology Clinic	Obihiro shi
Japan	Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital	Osaka
Japan	Kindai University Hospital	Osaka Sayama shi
Japan	Kume Clinic	Sakai-shi
Japan	Sapporo Skin Clinic	Sapporo shi
Japan	Tohoku University Hospital	Sendai
Japan	Osaka University Hospital	Suita-shi
Japan	Jitaikai Tachikawa dermatology clinic	Tachikawa
Japan	Shirasaki Dermatology Clinic	Takaoka-shi
Japan	Tokyo Medical University Hospital	Tokyo
Japan	Mie University Hospital	Tsu
Korea, Republic of	Pusan National University Hospital	Busan
Korea, Republic of	Seoul National University Bundang Hospital	Gyeonggi-do
Korea, Republic of	Hanyang University Medical Center	Seoul
Korea, Republic of	Konkuk University Medical Center	Seoul
Korea, Republic of	Kyung Hee University Hospital	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	The Catholic University of Korea Seoul St. Mary's Hospital	Seoul
Poland	Osteo-Medic s.c A. Racewicz, J Supronik	Bialystok
Poland	Specderm Poznanska sp j	Bialystok
Poland	Centrum Kliniczno Badawcze J. Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska	Elblag
Poland	Centrum Medyczne dr Rajzer Sp z o o	Krakow
Poland	Centrum Medyczne Promed	Krakow
Poland	Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna	Krakow
Poland	Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna	Lodz
Poland	Dermed Centrum Medyczne Sp z o o	Lodz
Poland	DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski s.c.	Osielsko
Poland	Clinical Research Center sp z o o MEDIC R s k	Poznan
Poland	SOLUMED Centrum Medyczne	Poznan
Poland	Klinika Ambroziak Dermatologia	Warszawa
Poland	Przychodnia Specjalistyczna High Med	Warszawa
Poland	Centrum Medyczne Oporow	Wroclaw
Poland	DERMMEDICA Sp.z o.o.	Wroclaw
Poland	WroMedica I.Bielicka, A.Strzalkowska s.c.	Wroclaw
Spain	Hosp. Gral. Univ. Dr. Balmis	Alicante
Spain	Hosp. Univ. de Cruces	Barakaldo
Spain	Hosp. de La Santa Creu I Sant Pau	Barcelona
Spain	Hosp. Univ. San Cecilio	Granada
Spain	Hosp. Univ. de Bellvitge	L'Hospitalet de Llobregat
Spain	Grupo Dermatologico Y Estetico Pedro Jaen	Madrid
Spain	Hosp. Gral. Univ. Gregorio Maranon	Madrid
Spain	Hosp. Univ. 12 de Octubre	Madrid
Spain	Hosp. Univ. de La Paz	Madrid
Spain	Hosp. Univ. de La Princesa	Madrid
Spain	Hosp. Univ. Infanta Leonor	Madrid
Spain	Hosp. Univ. I Politecni La Fe	Valencia
Taiwan	National Taiwan University Hospital Hsin Chu Branch	Hsin Chu
Taiwan	Chang Kung Memorial Hospital	Kaohsiung City
Taiwan	Taipei Medical University Shuang Ho Hospital	New Taipei City
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Mackay Memorial Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei
Taiwan	Linkou Chang Gung Memorial Hospital	Taoyuan
United Kingdom	Guy's and St Thomas' NHS Foundation Trust	London
United Kingdom	Royal Berkshire Hospital	Reading
United Kingdom	Salford Royal Hospital	Salford
United Kingdom	University Hospital Southampton NHS Foundation Trust	Southampton
United States	Hamilton Research, LLC.	Alpharetta	Georgia
United States	David Fivenson MD, Dermatology	Ann Arbor	Michigan
United States	Oakview Dermatology	Athens	Ohio
United States	Optima Research	Boardman	Ohio
United States	Tufts Medical Center	Boston	Massachusetts
United States	Illinois Dermatology Institute - Chicago Loop Office	Chicago	Illinois
United States	Michigan Center of Medical Research	Clarkston	Michigan
United States	Driven Research LLC	Coral Gables	Florida
United States	Modern Research Associates	Dallas	Texas
United States	Henry Ford Medical Center	Detroit	Michigan
United States	Windsor Dermatology	East Windsor	New Jersey
United States	Hamzavi Dermatology	Fort Gratiot	Michigan
United States	Johnson Dermatology	Fort Smith	Arkansas
United States	First OC Dermatology	Fountain Valley	California
United States	Center for Dermatology Clinical Research	Fremont	California
United States	Schweiger Dermatology Group	Hackensack	New Jersey
United States	Austin Institute for Clinical Research	Houston	Texas
United States	Center for Clinical Studies	Houston	Texas
United States	Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana
United States	Dermatology and Advanced Aesthetics	Lake Charles	Louisiana
United States	Fife Dermatology	Las Vegas	Nevada
United States	Dermatology Specialists	Louisville	Kentucky
United States	Skin Care Physicians of Georgia	Macon	Georgia
United States	Frontier Derm Partners CRO, LLC	Mill Creek	Washington
United States	Ziaderm Research, LLC	North Miami Beach	Florida
United States	Renstar Medical Research	Ocala	Florida
United States	Central Sooner Research	Oklahoma City	Oklahoma
United States	Skin Specialists	Omaha	Nebraska
United States	Austin Institute for Clinical Research	Pflugerville	Texas
United States	Medical Dermatology Specialists	Phoenix	Arizona
United States	Indiana Clinical Trial Center	Plainfield	Indiana
United States	Oregon Medical Research Center	Portland	Oregon
United States	Allcutis Research	Portsmouth	New Hampshire
United States	Health Concepts	Rapid City	South Dakota
United States	National Clinical Research	Richmond	Virginia
United States	Arlington Dermatology	Rolling Meadows	Illinois
United States	Integrative Skin Science and Research	Sacramento	California
United States	MediSearch Clinical Trials	Saint Joseph	Missouri
United States	Progressive Clinical Research	San Antonio	Texas
United States	Texas Dermatology and Laser Specialists	San Antonio	Texas
United States	Southern California Dermatology	Santa Ana	California
United States	Clinical Science Institute	Santa Monica	California
United States	Center for Dermatology and Plastic Surgery	Scottsdale	Arizona
United States	Northshore Medical Group	Skokie	Illinois
United States	Premier Clinical Research	Spokane	Washington
United States	Derm Research Center of New York, Inc.	Stony Brook	New York
United States	Forcare Clinical Research Inc	Tampa	Florida
United States	Center for Clinical Studies	Webster	Texas
United States	Dundee Dermatology	West Dundee	Illinois
United States	Wilmington Dermatology Center	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Canada,  Germany,  Hungary,  Japan,  Korea, Republic of,  Poland,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline to Week 16	Percentage of participants who achieve an IGA score of 0 or 1 and >=2-Grade improvement from baseline to Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).	Baseline and Week 16
Primary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16	Percentage of participants achieving PASI 90 response (>=90% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an IGA Score of 0 at Week 16	Percentage of participants who achieve an IGA score of 0 at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).	Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response From Baseline to Weeks 4 and 16	Percentage of participants achieving PASI 75 response (>=75% improvement in PASI from baseline) at Weeks 4 and 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline, Week 4, and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 90 Response at Week 8	Percentage of participants achieving PASI 90 response (>=90% improvement in PASI from baseline) at Week 8 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and Week 8
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16	Percentage of participants achieving PASI 100 response (100% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 and >=2 Grade Improvement From Baseline at Week 16	Percentage of participants achieving ss-IGA score of 0 or 1 and >=2 grade improvement from baseline to Week 16 will be reported. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Symptom and Signs Diary (PSSD) Symptom Score of 0 at Weeks 8 and 16	Percentage of participants achieving PSSD symptom score of 0 at Weeks 8 and 16 will be reported. The PSSD includes patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Weeks 8 and 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving >=4 Point Improvement From Baseline in PSSD Itch Score at Weeks 4 and 16	Percentage of participants achieving >=4 Point improvement from baseline in PSSD itch score at Weeks 4 and 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Baseline, Week 4, and Week 16
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving an IGA Score of 0 or 1 and >=2 Grade Improvement From Baseline at Weeks 16 and 24	Percentage of participants who achieve an IGA score of 0 or 1 and >=2 grade improvement from baseline at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).	Baseline, Week 16, and Week 24
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving an IGA Score of 0 at Weeks 16 and 24	Percentage of participants who achieve an IGA score of 0 at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).	Weeks 16 and 24
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 75 Response at Weeks 16 and 24	Percentage of participants achieving PASI 75 response (>=75% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline, Week 16 and Week 24
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 90 Response at Weeks 16 and 24	Percentage of participants achieving PASI 90 response (>=90% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline, Week 16, and Week 24
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 100 Response at Weeks 16 and 24	Percentage of participants achieving PASI 100 response (100% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline, Week 16, and Week 24
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants With PSSD Symptom Score of 0 at Week 16	Percentage of participants achieving PSSD symptom score 0 at Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Week 16
Secondary	Number of Participants with Adverse Events (AEs)	An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Up to 165 weeks
Secondary	Number of Participants with Serious Adverse Events (SAEs)	SAEs are any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, or is medically important.	Up to 165 weeks
Secondary	Change From Baseline in Body Surface Area (BSA) at Week 16	Change from baseline in BSA at Week 16 will be reported. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).	Baseline and Week 16
Secondary	Change from Baseline in PASI Total Score at Week 16	Change from baseline in PASI total score at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas are assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and Week 16
Secondary	Percent Improvement in PASI Score From Baseline at Week 16	Percent improvement in PASI score from Baseline at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline to Week 16	Percentage of participants achieving a sPGA-G Score of 0 or 1 and at least a 2-grade improvement from baseline to Week 16 will be reported. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline to Week 16	Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement from baseline to Week 16 will be reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16	Percent change from baseline in mNAPSI score at Week 16 will be reported. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's 10 fingernails are evaluated for 7 features. The first 3 features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next 4 features are scored 0 - absent or 1 - present and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0 to 13 per nail and 0 to 130 for all fingernails.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percent of Participants Achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16	Percent of participants achieving f-PGA score of 0 or 1 at Week 16 will be reported. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 (clear [0], minimal [1], mild [2], moderate [3], or severe [4]).	Week 16
Secondary	JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Symptom Score at Week 16	Change from baseline in PSSD symptom score at Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Sign Score at Week 16	Change from baseline in PSSD sign score at Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants With PSSD Sign Score of 0 at Week 16	Percentage of participants with PSSD sign score of 0 at Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16	Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 will be reported. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never [0], rarely [1], sometimes [2], often [3], or always [4]).	Week 16
Secondary	JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16	Percentage of participants achieving DLQI score of 0 or 1 at Week 16 will be reported. The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.	Week 16
Secondary	JNJ-77242113 and Placebo Group: Change From Baseline in Total DLQI Score at Week 16	Change from baseline in total DLQI score at Week 16 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.	Baseline and Week 16
Secondary	JNJ-77242113 and Placebo Group: Change from Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16	Change from baseline in domain scores of the PROMIS-29 score at Week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL survey, assessing each of the 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. The questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.	Baseline and Week 16
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving DLQI Score of 0 or 1 at Weeks 16 and 24	Percentage of participants achieving DLQI score of 0 or 1 at Weeks 16 and 24 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.	Weeks 16 and 24
Secondary	JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PSSD Symptom Score of 0 at Weeks 16 and 24	Percentage of participants achieving PSSD symptom score of 0 at Weeks 16 and 24 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.	Weeks 16 and 24
Secondary	Percentage of Participants Who Achieve PASI 75 Response After Week 24 Among PASI 75 Non-responders to Deucravacitinib at Week 24	Percentage of participants who achieve PASI 75 response (>=75% improvement in PASI) after Week 24 among PASI 75 Non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and from Week 24 through Week 156
Secondary	Percentage of Participants Who Achieve PASI 90 Response After Week 24 Among PASI 90 Non-responders to Deucravacitinib at Week 24	Percentage of participants who achieve PASI 90 response (>=90% improvement in PASI) after Week 24 among PASI 90 non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.	Baseline and from Week 24 through Week 156
Secondary	Percentage of Participants Achieving IGA Score of 0 or 1 after Week 24, Among Participants with IGA score >=2 at Week 24 in the Deucravacitinib Group	Percentage of participants achieving IGA score of 0 or 1 after Week 24, among participants with IGA score >=2 at Week 24 in the deucravacitinib group will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).	From Week 24 through Week 156